Gestational trophoblastic disease in Campinas, Brazil and persistency predictors

Purpose: To determine the prevalence of the gestational trophoblastic disease (GTD) and to evaluate the risk factors for persistence of the disease. Materials and Methods: A retrospective study with 152 women diagnosed with GTD at University of Campinas from 2006 to 2013. Frequencies, average, and standard deviation were evaluated for each variable and an exact Fisher test was utilized to study persistent disease risk factors. Results: The women were on average 25.81 ± 8.02 years old. The most prevalent blood type was O positive (49.6%). The diagnosis of complete mole was found in 64.8%, followed by partial mole in 32%, and choriocarcinoma in 3%. Complete mole developed invasive mole in 12.3%, the same occurred with 7.5% of the partial moles. No significant association was found between age, number of gestations, race, BMI or blood type and persistent mole. Conclusion: The complete mole is the most frequent GTD, and is at high risk for developing malignant forms.

Gestational trophoblastic disease; Persistent gestational trophoblastic disease; Hydatidiform mole.

[1] Sun S.Y., Amed A.M., Bertini A.M., Camano L.: “Incidencia de mola hidatiforme na Escola Paulista de Medicina”. Rev. Assoc. Med. Bras., 1992, 38, 217.

[2] Lybol C., Thomas C.M.G., Bulten J., Van Dijck J.A.A.M., Sweep F.C.G.J., Massurger L.F.A.G.: “Increase in the incidence os gestational disease in The Netherlands”. Gynecol. Oncol., 2011, 121, 334.

[3] Altieri A., Franceschi S., Ferlay J., Smith J., La Vecchia C.: “Epidemiology and aetiology of gestational trophoblastic diseases”. Lancet Oncol., 2003, 4, 670.

[4] Soares P.D., Maesta I., Costa O.L., Charry R.C., Dias A., Rudge M.V.: “Geographical distribuition and demographic characteristics of gestational trophoblastic disease”. J. Reprod. Med., 2010, 55, 305.

[5] Cheung A.N.: “Pathology of gestational trophoblastic diseases”. Best Pract. Res. Clin. Obstet. Gynaecol., 2003, 17, 849.

[6] Bagshawe K.D., Dent J., Webb J.: “Hydatiform mole in England and Wales 1973-83”. Lancet, 1986, 2, 6763.

[7] Soper J.T.: “Management of gestationaltrophoblasticdisease”. Oncology (Williston Park), 1993, 7, 68.

[8] Lurain J.R., Brewer J.I., Torok E.E., Halpern B.: “Natural history of hydatidiform mole afterprimaryevacuation”. Am. J. Obstet. Gynecol., 1983, 145, 591.

[9] Nakano R., Sasaki K., Yamoto M., Hata H.: “Trophoblasticdisease: analysis of 342 patients”. Gynecol. Obstet. Invest., 1980, 11, 237.

[10] Smith H.O.: “Gestational trophoblastic disease epidemiology and trends”. Clin. Obstet. Gynecol., 2003, 46, 541.

[11] Hancock B.W.: “Staging and classification of gestational trophoblastic disease”. Best Pract. Res. Clin. Obstet. Gynaecol., 2003, 17, 869.

[12] Tiezzi D.G., Andrade J.M., Reis F.J.C., Lombardi W., Marana H.R.C.: “Fatores de risco para doença trofoblástica gestacional persistente”. Rev. Bras. Ginecol. Obstet., 2005, 27, 331.

[13] Bandy L.C., Clarke-Pearson D.L., Hammond C.B.: “Malignant potential of gestational trophoblastic disease at the extreme ages of reproductive life”. Obstet. Gynecol., 1984, 64, 395.

[14] Brinton L.A., Bracken M.B., Connelly R.R.: “Choriocarcinoma incidence in the United States”. Am. J. Epidemiol., 1986, 123, 1094.

[15] Mungan T., Kuscu E., Dabakoglu T., Senoz S., Ugur M., Cobanoglu O.: “Hydatidiform mole: clinical analysis of 310 patients”. Int. J. Gynecol. Obstet., 1996, 52, 233.

[16] Maesta I., Rudge M.V.C., Abreu E.S., Dalben I., Peraçoli J.C.: “ Preditores clínicos e histopatológicos de tumor trofoblastico gestacional pós-mola hidatiforme completa”. Rev. Bras. Ginecol. Obstet., 2000, 22, 167.

[17] Hertig A.T., Mansell H.: “Hydatidiform mole and choriocarcinoma”. In: Tumors of the female sex organs. Part I, Atlas of Tumor Pathology, section 9, fasc. 33. Washington, DC: Armed Forces Institute of Pathology, 1956, 7.

[18] Delfs E.: “Chorionic gonadotropin determinations with hydatidiform mole and choriocarcinoma”. Ann. N. Y. Acad. Sci., 1959, 8, 125.

[19] Feltmate C.M., Batorfi J., Fulop V., Goldstein D.P., Doszpod J., Berkowitz R.S.: “Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation”. Obstet. Gynecol., 2003, 101, 732.

[20] Morrow C.P., Kletzky O.A., Disaia P.J., Townsend D.E., Mishell D.R., Nakamura R.M.: “Clinical and laboratory correlates of molar pregnancy and trophoblastic disease”. Am. J. Obstet. Gynecol., 1977, 128, 424.

[21] Pisal N., Tidy J., Hancock B.: “Gestational trophoblastic disease: is intensive follow up essential in all women?” BJOG, 2004, 111, 1449.

[22] Soper J.T.: “Staging and evaluation of gestational trophoblastic disease”. Clin. Obstet. Gynecol., 2003, 46, 570.

[23] Bracken M.B., Brinton L.A., Hayashi K.: “Epidemiology of hydatidiform mole and choriocarcinoma”. Epidemiol. Rev., 1984, 6, 52.

[24] World Health Organization (WHO), Scientific Group on Gestational Trophoblastic Disease: “Gestational trophoblastic diseases, Technical Report Series, 692”. Geneva: WHO, 1983. Available at: http://apps.who.int/iris/bitstream/10665/39169/1/WHO_TRS_692.pdf

[25] Goldstein D.P., Berkowitz R.S., Bernstein M.R.: “Management of molar pregnancy”. J. Reprod. Med., 1981, 26, 208.

[26] Curry S.L., Hammond C.B., Tyrey L., Creasman W.T., Parker R.T.: “Hydatidiform mole: diagnosis management, and long-term followup of 347 patients”. Obstet. Gynecol., 1975, 45, 1.

[27] Park T.K., Kim S.N., Lee S.K.: “Analysis of risk factors for postmolar trophoblastic disease: categorization of risk factors and effect of prophylactic chemotherapy”. Yonsei Med. J., 1996, 37, 412.

[28] Tangtrakul S., Srisupundit S., Linasmita V., Bullangpoti S., Bhamarapravati Y.: “The risk factors in the development of persistent trophoblastic disease following hydatidiform mole”. J. Med. Assoc. Thai, 1990, 73, 33.

[29] Yazaki-Sun S., Monteleone P.P.R., Bertini A.M., Camano L.: “A importância da idade da paciente no prognóstico da mola hidatiforme”. Ars. Cvrandi, 1992, 25, 34.